Unicycive Total Assets vs Common Stock Total Equity Analysis
UNCY Stock | USD 1.03 0.05 4.63% |
Unicycive Therapeutics financial indicator trend analysis is much more than just breaking down Unicycive Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Unicycive Therapeutics is a good investment. Please check the relationship between Unicycive Therapeutics Total Assets and its Common Stock Total Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.
Total Assets vs Common Stock Total Equity
Total Assets vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Unicycive Therapeutics Total Assets account and Common Stock Total Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Unicycive Therapeutics' Total Assets and Common Stock Total Equity is 0.77. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Unicycive Therapeutics, assuming nothing else is changed. The correlation between historical values of Unicycive Therapeutics' Total Assets and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Unicycive Therapeutics are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Total Assets i.e., Unicycive Therapeutics' Total Assets and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.77 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Assets
Total assets refers to the total amount of Unicycive Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Unicycive Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Unicycive Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 12.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.4 M in 2024.
Unicycive Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Unicycive Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Unicycive Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Current Liabilities | 903K | 2.9M | 2.1M | 3.3M | 17.5M | 18.4M | |
Retained Earnings | (3.7M) | (5.9M) | (15.9M) | (34.0M) | (64.5M) | (61.3M) | |
Accounts Payable | 322K | 184K | 742K | 892K | 821K | 553.9K | |
Total Current Assets | 19K | 204K | 18.4M | 2.6M | 13.4M | 14.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.Note that the Unicycive Therapeutics information on this page should be used as a complementary analysis to other Unicycive Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Unicycive Stock analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Unicycive Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Unicycive Therapeutics. If investors know Unicycive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Unicycive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Return On Assets (0.40) | Return On Equity (2.29) |
The market value of Unicycive Therapeutics is measured differently than its book value, which is the value of Unicycive that is recorded on the company's balance sheet. Investors also form their own opinion of Unicycive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Unicycive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Unicycive Therapeutics' market value can be influenced by many factors that don't directly affect Unicycive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Unicycive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Unicycive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Unicycive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.